ArticleArchives of orthopaedic and trauma surgery2026
Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBariatric surgery has been associated with increased risks of revision surgery following total knee arthroplasty (TKA), raising concerns about its safety for weight management in this population. Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacologic alternative, though its impact on TKA outcomes remains underexplored. This study compares TKA outcomes between patients who have a history of bariatric surgery and semaglutide use.
methodsA retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650). Demographics, BMI trends, 90-day complications, and revision rates were compared using statistical analyses, including Kaplan-Meier survivorship and multivariate logistic regression.
resultsBariatric surgery patients experienced significantly more 90-day emergency department (ED) visits (7.9 [BS] vs. 5.7 [SU] vs. 4.0% [C], P < 0.001) and lower 10-year implant survival (90.3 [BS] vs. 94.5% [C], P = 0.039). Multivariate analysis demonstrated that a history of BS independently predicted increased odds of ED visits (OR 1.79, P = 0.005) and revision (OR 1.71, P = 0.028), while SU was not a significant predictor of adverse outcomes. The BS group achieved the largest preoperative BMI reduction (–1.8 kg/m²) vs. SU (–0.7 kg/m²) and controls (+ 2.1 kg/m²). Notably, the SU cohort regained 1.7 kg/m² within three years post-TKA.
conclusionWhile semaglutide use before TKA was associated with only modest weight loss, it appeared safe and yielded favorable short-term outcomes. Bariatric surgery, though more effective for weight reduction, carried higher complication rates and inferior long-term implant survivorship. Further research is needed to clarify semaglutide’s long-term role in TKA patients with obesity. LEVEL OF EVIDENCE: III.
Indexed as
Identifiers
41718773What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.